{"organizations": [], "uuid": "01bfd9a655ecce94b010679f3280cb2a6eec2445", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/01/globe-newswire-evogene-files-annual-report-for-the-year-ended-december-31-2017.html", "country": "US", "domain_rank": 767, "title": "Evogene Files Annual Report for the Year Ended December 31, 2017", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-04-01T15:00:00.000+03:00", "replies_count": 0, "uuid": "01bfd9a655ecce94b010679f3280cb2a6eec2445"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/01/globe-newswire-evogene-files-annual-report-for-the-year-ended-december-31-2017.html", "ord_in_thread": 0, "title": "Evogene Files Annual Report for the Year Ended December 31, 2017", "locations": [], "entities": {"persons": [{"name": "evogene", "sentiment": "none"}], "locations": [{"name": "rehovot", "sentiment": "none"}, {"name": "israel", "sentiment": "none"}], "organizations": [{"name": "tase", "sentiment": "negative"}, {"name": "evogene ltd.", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "company", "sentiment": "none"}, {"name": "cpb", "sentiment": "none"}, {"name": "u.s. securities and exchange commission", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "REHOVOT, Israel, April 01, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique Computational Predictive Biology (CPB) platform, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commission (the “SEC”).\nThe annual report, which contains the Company's audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov/ as well as via the Company’s investor relations website at http://www.evogene.com/investor-relations . The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to the Company Media Contact: ir@evogene.com .\nAbout Evogene:\nEvogene (NASDAQ:EVGN) (TASE:EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique predictive biology platform incorporating deep scientific understandings and advanced computational technologies. This platform is utilized by the Company to discover and develop innovative ag-chemical, ag-biological and ag-seed products (GM and non GM), and by two subsidiaries; Evofuel, focused on castor seeds, and Biomica, focused on human microbiome therapeutics. Through its collaborations with world-leading agricultural companies such as BASF, Bayer, DuPont, Monsanto and Syngenta, Evogene has licensed genes, small molecules and microbes to partners under milestone and royalty bearing agreements. For more information, please visit www.evogene.com\nThis press release contains \"forward-looking statements\" relating to future events. These statements may be identified by words such as \"may\", \"could\", “expects”, \"intends\", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.\nContact:\nNir Zalik\nIR/PR manager\nE: IR@evogene.com\nT: (+972)-8-931-1963\nUS Investor Relations\nVivian Cervantes\nPCG Advisory\nE: vivian@pcgadvisory.com\nT: 646-863-6274\nSource:Evogene Ltd.", "external_links": ["https://www.globenewswire.com/Tracker?data=wdmO6Ey5jTTdn9-HH1zIfnaU3gIhH6z5jTx7GtTYVzT2zAD8Wt0R_d_qXhA1PNtj8cjXFc8tYQriYnohQQ8WAw==", "https://www.globenewswire.com/Tracker?data=0uX0CCbn11oHafsYPwQ78dzTl6Rh11D_8806Zi1c2q1BDhrqUY_9jbwQPg-EUgeeqhVClVjxXlukmfzE7-mg0w==", "https://www.globenewswire.com/Tracker?data=fs66G_SwOJp_bIdN-8wj4tIrRPrcwo3xBUm3LdiGZdMwfWDMR5gxzSUSKl7Z_o_IP1i_O881aqmGbsz_B8hSEw==", "http://www.sec.gov/", "https://www.globenewswire.com/Tracker?data=j-pG7WGLW2c_bPbuk5S3ZFozR5uBfpvrFSGdpfk52lbPyGYtKFqR98EVnKpEuRlbqpphslXNEfiH3T0g9mBF59dLE4n5Y9w374e1APPIWCg=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/d0a3903e-5dcd-4f20-870c-6b58c1959756", "https://www.globenewswire.com/Tracker?data=SMXyKxSOQHKl9CSvW9dXBssEIZf8sGLcCRWNjZocq3Bqa7RQcf143on_wM_dYbPbRrEDOazUL1SiSmd6G63wyQ==", "http://www.evogene.com/investor-relations", "https://www.globenewswire.com/Tracker?data=fs66G_SwOJp_bIdN-8wj4rEhHA1n8pZuso6yQuSLPxMT0cMb9MSAiPwazRq257yGv_p8KXmkV7B4THKrzCJTMcXGXf9PXg5KNBsJvU-ieXQeUdeTdjb9a5Zk0qRXJ01gVkzz4rJ45J-xK8j-aWG--Q=="], "published": "2018-04-01T15:00:00.000+03:00", "crawled": "2018-04-01T14:32:18.054+03:00", "highlightTitle": ""}